Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers

Page 1 of 2

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. The Standard and Poor’s 500 Index returned 7.6% over the 12-month period ending November 21, while more than 51% of the constituents of the index underperformed the benchmark. Hence, a random stock picking process will most likely lead to disappointment. At the same time, the 30 most favored mid-cap stocks by the best performing hedge funds monitored by Insider Monkey generated a return of 18% over the same time span. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That’s why we are going to go over recent hedge fund activity in MEI Pharma Inc (NASDAQ:MEIP).

Is MEI Pharma Inc (NASDAQ:MEIP) ready to rally soon? Hedge funds are certainly betting on the stock. The number of bullish hedge fund investments experienced an increase of 3 recently. At the end of this article we will also compare MEIP to other stocks including AMREP Corporation (NYSE:AXR), Turtle Beach Corp (NASDAQ:HEAR), and Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to get a better sense of its popularity.

Follow Mei Pharma Inc. (NASDAQ:MEIP)
Trade (NASDAQ:MEIP) Now!

We follow over 700 hedge funds and other institutional investors and by analyzing their quarterly 13F filings, we identify stocks that they are collectively bullish on and develop investment strategies based on this data. One strategy that outperformed the market over the last year involves selecting the 100 best-performing funds and identifying the 30 mid-cap stocks that they are collectively most bullish on. Over the past year, this strategy generated returns of 18%, topping the 8% gain registered by S&P 500 ETFs. We launched this strategy 2.5 years ago and it returned more than 39% since then, vs. 22% gain registered by the S&P 500 ETFs.

test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease,

science photo/Shutterstock.com

Hedge fund activity in MEI Pharma Inc (NASDAQ:MEIP)

At Q3’s end, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, a gain of 100% from one quarter earlier. With hedgies’ sentiment swirling, there exists an “upper tier” of notable hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Jim Simons’ Renaissance Technologies has the biggest position in MEI Pharma Inc (NASDAQ:MEIP), worth close to $2.1 million. Coming in second is Iguana Healthcare Management, led by Stuart Weisbrod, which holds a $0.5 million position. Other hedge funds and institutional investors with similar optimism comprise Millennium Management, one of the 10 largest hedge funds in the world, Gregory Fraser, Rudolph Kluiber, and Timothy Krochuk’s GRT Capital Partners, and Ken Griffin’s Citadel Investment Group. We should note that GRT Capital Partners is among our list of the 100 best performing hedge funds, which is based on the performance of their 13F long positions in non-micro-cap stocks.

Page 1 of 2